Environmental Pollution Risk Associated with Research and Manufacturing
First written in FY2016. 4 of 10 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2025: 3 of 14 companies on the "Worse" side.
0 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The identified risks and opportunities were analyzed, taking into account their financial impact and frequency of occurrence, and response measures were evaluated. "CO2 emissions 17,900 12,956 (△27.6%)"」
The company continues its scenario analysis of climate change risks and opportunities and evaluation of response measures, and has disclosed that CO2 emissions in fiscal 2024 were 27.6% lower than in fiscal 2013. - FY2025AdvancedAnnual report
「The company identified climate change-related risks and opportunities using 1.5°C and 4°C scenarios to assess the impact of climate change on its business. It analyzed the identified risks and opportunities, taking into account their financial impact and frequency of occurrence, and evaluated response measures.」
Under the 1.5°C and 4°C scenarios, the company identified risks including carbon taxes, business interruptions, fish oil shortages and water shortages, and organized them by timing, impact and response measures. - FY2024AdvancedAnnual report
「The company identified climate change-related risks and opportunities using 1.5°C and 4°C scenarios to assess the impact of climate change on its business.」
Building on its previous analysis of climate change risks and consideration of related disclosures, the company has disclosed the identification of risks and opportunities under 1.5°C and 4°C scenarios, impact analysis and evaluation of response measures. - FY2023AdvancedAnnual report
「The company has set a target of achieving carbon neutrality by 2050 and reducing CO2 emissions by 46% in fiscal 2030 from fiscal 2013 levels.」
Building on the analysis of climate change risks and consideration of related disclosures described in FY2022, the company has set targets of carbon neutrality by 2050 and a 46% reduction in CO2 emissions in fiscal 2030 from fiscal 2013 levels. - FY2022Addition of climate change riskAnnual report
「The company will also analyze the impact of climate change-related risks on its business activities, earnings and other areas, and will consider making disclosures.」
In addition to the existing risk of environmental pollution associated with research and manufacturing, the company has newly described its analysis of the impact of climate change risk and consideration of related disclosures. - FY2021RestatedAnnual report
「Some of the chemicals used in the research and manufacturing processes for pharmaceuticals and other products may adversely affect human health or ecosystems. If these substances cause serious environmental impacts, such as soil or air pollution, they may materially affect operating results and financial condition through measures to identify the causes of the pollution and address surrounding communities, as well as declines in sales resulting from reputational damage.」
The risks of addressing surrounding communities, reputational damage and declining sales resulting from environmental pollution associated with research and manufacturing have been reconfirmed. - FY2020RestatedAnnual report
「Some of the chemicals used in the research and manufacturing processes for pharmaceuticals and other products may adversely affect human health or ecosystems. If these substances cause serious environmental impacts, such as soil or air pollution, they may materially affect operating results and financial condition.」
The risk of environmental pollution associated with research and manufacturing is reiterated. - FY2019RestatedAnnual report
「Some of the chemicals used in the research and manufacturing of pharmaceuticals and other products may adversely affect human health or ecosystems. If these chemicals cause serious environmental impacts, such as soil or air pollution, this could have a material impact on operating results and financial condition.」
The risk of environmental pollution associated with research and manufacturing is reiterated. - FY2018RestatedAnnual report
「Some of the chemicals used in the research and manufacturing of pharmaceuticals and other products may adversely affect human health or ecosystems. If these chemicals cause serious environmental impacts, such as soil or air pollution, this could have a material impact on operating results and financial condition.」
The risk of environmental pollution associated with research and manufacturing is reiterated. - FY2016First statedAnnual report
「Some of the chemicals used in the research and manufacturing of pharmaceuticals and other products may adversely affect human health or ecosystems. If these chemicals cause serious environmental impacts, such as soil or air pollution, this could have a material impact on operating results and financial condition.」
Environmental impacts have been explicitly identified as a business and other risk.